Advisory Committee on Immunization Practices (ACIP), 58663-58664 [2021-23222]
Download as PDF
Federal Register / Vol. 86, No. 202 / Friday, October 22, 2021 / Notices
GENERAL SERVICES
ADMINISTRATION
[Notice MG–2021–03; Docket No. 2021–
0002; Sequence No. 25]
Office of Federal High-Performance
Green Buildings; Green Building
Advisory Committee; Notification of
Upcoming Web-Based Meetings
Office of Government-wide
Policy, General Services Administration
(GSA).
ACTION: Notice of public meetings.
AGENCY:
Notice of these web-based
public meetings/conference calls is
being provided according to the
requirements of the Federal Advisory
Committee Act. This notice provides the
schedule for one full Committee
meeting of the Green Building Advisory
Committee (Committee), which is open
to the public. Interested individuals
must register to attend and provide
public comment as instructed below
under SUPPLEMENTARY INFORMATION.
DATES: The Green Building Advisory
Committee will hold a web-based
meeting on Tuesday, November 16,
2021, from 11:00 a.m. to 4:00 p.m.,
Eastern Time (ET).
FOR FURTHER INFORMATION CONTACT:
Michael Bloom, Designated Federal
Officer, Office of Federal HighPerformance Green Buildings, Office of
Government-wide Policy, General
Services Administration, at
michael.bloom@gsa.gov or 312–805–
6799. Additional information about the
Committee, including meeting materials
and agendas, will be available on-line at
https://www.gsa.gov/gbac.
SUPPLEMENTARY INFORMATION:
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
November 16, 2021 Meeting Agenda
• Updates and introductions
• Federal Building Decarbonization
Task Group: Findings &
Recommendations
• Environmental Justice and Equity
Task Group: Findings &
Recommendations
• Energy Storage Task Group: Final
Vote to Accept Advice Letter
• New committee directions & topics to
explore
• Public comment
• Next steps and closing comments
Kevin Kampschroer,
Federal Director, Office of Federal HighPerformance Green Buildings, Office of
Government-wide Policy, General Services
Administration.
[FR Doc. 2021–23068 Filed 10–21–21; 8:45 am]
BILLING CODE 6820–14–P
Background
The Administrator of GSA established
the Committee on June 20, 2011
(Federal Register/Vol. 76, No. 118)
pursuant to Section 494 of the Energy
Independence and Security Act of 2007
(EISA, 42 U.S.C. 17123). Under this
authority, the Committee provides
independent policy advice and
recommendations to GSA to advance
federal building innovations in
planning, design, and operations to
reduce costs, enable agency missions,
enhance human health and
performance, and minimize
environmental impacts.
Procedures for Attendance and Public
Comment
Contact Michael Bloom, at
michael.bloom@gsa.gov, to register to
attend this public web-based meetings.
To register, submit your full name,
VerDate Sep<11>2014
organization, email address, phone
number. Requests to attend this webbased meeting must be received by 5:00
p.m. ET, on Wednesday, November 10,
2021. Meeting call-in information will
be provided to interested parties who
register by the deadline. (GSA will be
unable to provide technical assistance to
any listener experiencing technical
difficulties. Testing access to the webbased meeting site before the meetings
is recommended.)
Contact Mr. Bloom to register to
provide public comment during the
November 16th, 2021 meeting public
comment period. Registered speakers/
organizations will be allowed a
maximum of five minutes each and will
need to provide written copies of their
presentations. Requests to provide
public comment at the Committee
meeting must be received by 5:00 p.m.,
ET, on Monday, November 8, 2021.
17:47 Oct 21, 2021
Jkt 256001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2021–0112]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting of the Advisory
SUMMARY:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
58663
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. Time will be available for public
comment. The meeting will be webcast
live via the World Wide Web; for more
information on ACIP please visit the
ACIP website: https://www.cdc.gov/
vaccines/acip/.
DATES: The meeting will be held on
November 2–3, 2021, from 10:00 a.m. to
5:00 p.m., EDT (times subject to
change). The public may submit written
comments from October 22, 2021
through November 3, 2021.
ADDRESSES: You may submit comments
identified by Docket No. CDC–2021–
0112 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS H24–8, Atlanta, Georgia 30329–
4027, Attn: ACIP Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
Written public comments submitted
up to 72 hours prior to the ACIP
meeting will be provided to ACIP
members before the meeting.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, Georgia 30329–
4027; Telephone: (404) 639–8367;
Email: ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 41 CFR 102–3.150(b),
less than 15 calendar days’ notice is
being given for this meeting due to the
exceptional circumstances of the
COVID–19 pandemic and rapidly
evolving COVID–19 vaccine
development and regulatory processes.
The Secretary of Health and Human
Services has determined that COVID–19
is a Public Health Emergency. A notice
of this ACIP meeting has also been
posted on CDC’s ACIP website at: https://
www.cdc.gov/vaccines/acip/.
In addition, CDC has sent notice of this
ACIP meeting by email to those who
subscribe to receive email updates about
ACIP.
Purpose: The committee is charged
with advising the Director, CDC, on the
E:\FR\FM\22OCN1.SGM
22OCN1
58664
Federal Register / Vol. 86, No. 202 / Friday, October 22, 2021 / Notices
use of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children program, along
with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the CDC Director and
appear on CDC immunization schedules
must be covered by applicable health
plans.
Matters To Be Considered: The agenda
will include discussions on adult
immunization schedule, child/
adolescent immunization schedule,
Ebola vaccine, hepatitis vaccines,
Orthopoxviruses vaccine and COVID
vaccines. Recommendation votes on
adult immunization schedule, child/
adolescent immunization schedule,
hepatitis vaccine, Orthopoxviruses
vaccine, Ebola vaccine and COVID
vaccines are scheduled. No Vaccines for
Children votes are scheduled. Agenda
items are subject to change as priorities
dictate. For more information on the
meeting agenda visit https://
www.cdc.gov/vaccines/acip/meetings/
meetings-info.html.
lotter on DSK11XQN23PROD with NOTICES1
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on October 22, 2021. Written
VerDate Sep<11>2014
17:47 Oct 21, 2021
Jkt 256001
comments must be received on or before
November 3, 2021.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the November 2–3,
2021 ACIP meeting must submit a
request at https://www.cdc.gov/vaccines/
acip/meetings/ no later than 11:59 p.m.,
EDT, October 31, 2021, according to the
instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by November 1, 2021. To accommodate
the significant interest in participation
in the oral public comment session of
ACIP meetings, each speaker will be
limited to 3 minutes, and each speaker
may only speak once per meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–23222 Filed 10–20–21; 4:15 pm]
BILLING CODE 4163–18–P
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–2567, CMS–
10790 and CMS–10463]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995 (the
PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
December 21, 2021.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number: ll, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
SUMMARY:
E:\FR\FM\22OCN1.SGM
22OCN1
Agencies
[Federal Register Volume 86, Number 202 (Friday, October 22, 2021)]
[Notices]
[Pages 58663-58664]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-23222]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2021-0112]
Advisory Committee on Immunization Practices (ACIP)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. Time will be available for
public comment. The meeting will be webcast live via the World Wide
Web; for more information on ACIP please visit the ACIP website: https://www.cdc.gov/vaccines/acip/.
DATES: The meeting will be held on November 2-3, 2021, from 10:00 a.m.
to 5:00 p.m., EDT (times subject to change). The public may submit
written comments from October 22, 2021 through November 3, 2021.
ADDRESSES: You may submit comments identified by Docket No. CDC-2021-
0112 by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, Georgia 30329-4027, Attn: ACIP
Meeting.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Written public comments submitted up to 72 hours prior to the ACIP
meeting will be provided to ACIP members before the meeting.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE, MS-H24-8, Atlanta, Georgia 30329-4027; Telephone: (404) 639-
8367; Email: [email protected].
SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102-3.150(b), less
than 15 calendar days' notice is being given for this meeting due to
the exceptional circumstances of the COVID-19 pandemic and rapidly
evolving COVID-19 vaccine development and regulatory processes. The
Secretary of Health and Human Services has determined that COVID-19 is
a Public Health Emergency. A notice of this ACIP meeting has also been
posted on CDC's ACIP website at: https://www.cdc.gov/vaccines/acip/. In addition, CDC has sent notice of this ACIP meeting by
email to those who subscribe to receive email updates about ACIP.
Purpose: The committee is charged with advising the Director, CDC,
on the
[[Page 58664]]
use of immunizing agents. In addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children program, along with
schedules regarding dosing interval, dosage, and contraindications to
administration of vaccines. Further, under provisions of the Affordable
Care Act, section 2713 of the Public Health Service Act, immunization
recommendations of the ACIP that have been approved by the CDC Director
and appear on CDC immunization schedules must be covered by applicable
health plans.
Matters To Be Considered: The agenda will include discussions on
adult immunization schedule, child/adolescent immunization schedule,
Ebola vaccine, hepatitis vaccines, Orthopoxviruses vaccine and COVID
vaccines. Recommendation votes on adult immunization schedule, child/
adolescent immunization schedule, hepatitis vaccine, Orthopoxviruses
vaccine, Ebola vaccine and COVID vaccines are scheduled. No Vaccines
for Children votes are scheduled. Agenda items are subject to change as
priorities dictate. For more information on the meeting agenda visit
https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: The docket will be opened to receive
written comments on October 22, 2021. Written comments must be received
on or before November 3, 2021.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the November 2-3, 2021 ACIP meeting must
submit a request at https://www.cdc.gov/vaccines/acip/meetings/ no later
than 11:59 p.m., EDT, October 31, 2021, according to the instructions
provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by November 1, 2021. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to 3 minutes, and each speaker
may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-23222 Filed 10-20-21; 4:15 pm]
BILLING CODE 4163-18-P